Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care

The Pharmacogenomics Journal volume 20, pages 831–839 (2020)Cite this article

Subjects

Abstract

Hypoglycemia is a common complication among type 2 diabetes mellitus (T2DM) patients receiving sulfonylurea therapy. The aim of this study was to determine if genetic contributions to sulfonylurea pharmacokinetics or pharmacodynamics substantially affect the risk of hypoglycemia in these patients. In a retrospective case–control study in European American patients with T2DM, we examined the potential association between CYP2C9 reduced-function variants and sulfonylurea-related hypoglycemia. We also explored the relationship between sulfonylurea-related hypoglycemia and several candidate genetic variants previously reported to alter the response to sulfonylureas. We detected no evidence of association between CYP2C9 reduced-function alleles or any of the candidate genetic variants and sulfonylurea-related hypoglycemia. In conclusion, we identified no clinically significant predictors of hypoglycemia among genes associated with sulfonylurea pharmacokinetics or pharmacodynamics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Flow diagram of case and control identification.

Similar content being viewed by others

References

  1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011;8:228–36.

    PubMed  Google Scholar 

  2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125:302.e1–7.

    Google Scholar 

  4. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes. 2011;4:251.

    PubMed  PubMed Central  Google Scholar 

  6. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–9.

    Google Scholar 

  7. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.

    CAS  PubMed  Google Scholar 

  8. Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010;8:359–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhou S-F, Zhou Z-W, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 2010;278:165–88.

    CAS  PubMed  Google Scholar 

  10. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44:1209–25.

    CAS  PubMed  Google Scholar 

  11. Klen J, Dolžan V, Janež A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol. 2014;70:421–8.

    CAS  PubMed  Google Scholar 

  12. Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. Pharmacogenom J. 2016;16:209–19.

    CAS  Google Scholar 

  13. Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 2008;31:1939–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Nikolac N, Simundic A-M, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 2009;40:387–92.

    CAS  PubMed  Google Scholar 

  15. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pr. 2007;77:58–61.

    CAS  Google Scholar 

  16. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5’-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:2334–9.

    CAS  PubMed  Google Scholar 

  17. Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012;23:245–9.

    CAS  PubMed  Google Scholar 

  18. Chistiakov DA, Potapov VA, Smetanina SA, Bel’chikova LN, Suplotova LA, Nosikov VV. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. Acta Diabetol. 2011;48:227–35.

    CAS  PubMed  Google Scholar 

  19. Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X, et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia. 2014;57:746–53.

    CAS  PubMed  Google Scholar 

  20. Schroner Z, Javorský M, Halušková J, Klimčáková L, Babjaková E, Fabianová M, et al. Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas. Physiol Res. 2012;61:177–83.

    CAS  PubMed  Google Scholar 

  21. Schroner Z, Dobrikova M, Klimcakova L, Javorsky M, Zidzik J, Kozarova M, et al. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit. 2011;17:CR392–396.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Becker ML, Aarnoudse A-JLHJ, Newton-Cheh C, Hofman A, Witteman JCM, Uitterlinden AG, et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genom. 2008;18:591–7.

    CAS  Google Scholar 

  23. Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009;41:387–90.

    CAS  PubMed  Google Scholar 

  24. Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pr. 2012;98:119–24.

    CAS  Google Scholar 

  25. Holstein JD, Kovacs P, Patzer O, Stumvoll M, Holstein A. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics. 2012;13:5–7. author reply 9-10

    CAS  PubMed  Google Scholar 

  26. Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics. 2010;11:1743–50.

    CAS  PubMed  Google Scholar 

  27. Holstein JD, Patzer O, Körner A, Stumvoll M, Kovacs P, Holstein A. Genetic variants in GCKR, GIPR, ADCY5 and VPS13C and the risk of severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013;121:54–57.

    CAS  PubMed  Google Scholar 

  28. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84:362–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Ragia G, Tavridou A, Elens L, Van Schaik R, Manolopoulos V. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Exp Clin Endocrinol Diabetes. 2014;122:60–63.

    CAS  PubMed  Google Scholar 

  30. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011;31:1192–207.

    CAS  PubMed  Google Scholar 

  31. StataCorp. Stata statistical software: release 14. College Station, TX: StataCorp LP; 2015.

    Google Scholar 

  32. Holstein A, Plaschke A, Ptak M, Egberts E-H, El-Din J, Brockmöller J, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60:103–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Gökalp O, Gunes A, Cam H, Cure E, Aydın O, Tamer MN, et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol. 2011;67:1223–9.

    PubMed  Google Scholar 

  34. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009;10:1781–7.

    CAS  PubMed  Google Scholar 

  35. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol. 2011;67:471–6.

    CAS  PubMed  Google Scholar 

  36. Surendiran A, Pradhan SC, Agrawal A, Subrahmanyam DKS, Rajan S, Anichavezhi D, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol. 2011;67:797–801.

    CAS  PubMed  Google Scholar 

  37. Dujic T, Zhou K, Donnelly LA, Leese G, Palmer CNA, Pearson ER. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: a GoDARTS Study. Diabetes Obes Metab. 2018;20:211–4.

    CAS  PubMed  Google Scholar 

  38. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci. 2008;105:1733–8.

    CAS  PubMed  Google Scholar 

  39. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics. 2009;10:579–99.

    CAS  PubMed  Google Scholar 

  40. Qin W, Zhang R, Hu C, Wang C, Lu J, Yu W, et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Acta Pharmacol Sin. 2010;31:450–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R. Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med. 2007;4:157–69.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Elliot DJ, Suharjono null, Lewis BC, Gillam EMJ, Birkett DJ, Gross AS, et al. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol. 2007;64:450–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Lee S-J. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet. 2012;3:318.

    PubMed  Google Scholar 

  44. Scott SA, Sangkuhl K, Shuldiner AR, Hulot J-S, Thorn CF, Altman RB, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genom. 2012;22:159–65.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by National Institutes of Health grants R01GM109145 and R35GM131770. VKK is supported by K23GM117395. The datasets used for the analyses described were obtained from Vanderbilt University Medical Center resources, BioVU, and the Synthetic Derivative, which are supported by institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Genetic Medicine and Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    Sabrina L. Mitchell

  2. Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA

    Daniel A. Carranza Leon, Sandip Chaugai, Vivian K. Kawai & C. Michael Stein

  3. Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    Rebecca T. Levinson

  4. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    Wei-Qi Wei

Authors
  1. Sabrina L. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Carranza Leon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandip Chaugai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vivian K. Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rebecca T. Levinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei-Qi Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Michael Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabrina L. Mitchell.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitchell, S.L., Leon, D.A.C., Chaugai, S. et al. Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. Pharmacogenomics J 20, 831–839 (2020). https://doi.org/10.1038/s41397-020-0171-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-020-0171-4

This article is cited by

Search

Advanced search

Quick links